Form 8-K - Current report:
SEC Accession No. 0001193125-25-279074
Filing Date
2025-11-13
Accepted
2025-11-13 08:15:20
Documents
13
Period of Report
2025-11-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d92825d8k.htm   iXBRL 8-K 26765
2 EX-10.1 d92825dex101.htm EX-10.1 64441
  Complete submission text file 0001193125-25-279074.txt   227289

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lbrx-20251110.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lbrx-20251110_lab.xml EX-101.LAB 18736
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lbrx-20251110_pre.xml EX-101.PRE 11710
15 EXTRACTED XBRL INSTANCE DOCUMENT d92825d8k_htm.xml XML 3772
Mailing Address 575 MADISON AVENUE NEW YORK NY 10022
Business Address 575 MADISON AVENUE NEW YORK NY 10022 917-450-6581
LB PHARMACEUTICALS INC (Filer) CIK: 0001691082 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42831 | Film No.: 251475551
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)